Mylan Faces Patent Suits Over Generic Estradiol

Law360, New York (February 24, 2011, 7:19 PM EST) -- Units of Novartis AG and Hisamitsu Pharmaceutical Co. Inc. accused Mylan Inc. of infringing two of their patents by seeking to market a generic estradiol transdermal system in a pair of lawsuits filed this week.

One of the suits, lodged Thursday in the U.S. District Court for the District of Vermont, took Mylan and two subsidiaries to task over an abbreviated new drug application they submitted to the U.S. Food and Drug Administration.

A nearly identical suit was filed two days earlier in the U.S. District...
To view the full article, register now.